Amwell
Amwell's revenue fell 2.0% to $249 million in fiscal 2025. Its operating margin was −42.2%, up from −85.5% a year earlier. Free cash flow was −$66 million. The diluted share count rose 7.0%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Amwell does
Amwell sells software that lets hospitals, health insurers and employers offer doctor visits and other care online. Its clients run the programs under their own names. Patients can see a doctor by video for urgent care, primary care, mental health and follow-ups, often by clicking a link with no app to download. Inside hospitals, the same software connects doctors with specialists, for example for stroke care or remote nursing, and Amwell sells carts and devices, called Carepoints, that turn screens into video stations.
Amwell earns most of its money from recurring subscription fees for its platform, plus related services and Carepoint sales. When a client needs clinicians, its affiliated network, Amwell Medical Group, supplies them in all 50 states. Its clients are concentrated: its largest, the insurer Elevance Health, accounted for 31% of revenue in 2025. It names Teladoc, Included Health, Microsoft, Amazon, Zoom and electronic health record companies such as Epic among its competitors.
At the end of 2025 Amwell served about 50 health plans covering more than 90 million people, and about 80 large US health systems. Its platform handled more than 4.5 million virtual visits that year. It had 562 full-time employees, most in the United States and the rest mainly in Ireland, Israel, Colombia and the UK.
Its biggest risks, as it describes them
- A large share of its revenue comes from a few clients, led by Elevance Health, and losing one would hurt.
- It has a history of losses and says it may never become profitable.
- Online care is still a young market and may grow more slowly than it expects or draw bad publicity.
- It faces strong competition from telehealth firms, big technology companies and health record providers.
- Its work for the US military's Defense Health Agency may not continue on similar financial terms.
Income statement
Amwell lost money in fiscal 2025: a net loss of $96 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | — | 538 | 372 | 228 | 182 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.8x | 5.5x | 4.8x | 2.9x | 3.4x |
| Quick ratio | 5.8x | 5.4x | 4.7x | 2.8x | 3.4x |
Cash flow
Projections
Project Amwell's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Amwell says to expect
- Fourth quarter 2026: adjusted EBITDA
Q4 adjusted EBITDA expected to in the range of $0 million to $1 million.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $4,938 of Amwell shares on the open market, and 6 insiders sold $792,528, $98,882 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Mark HirschhornChief Financial Officer | Sold | 10,751 | $11.80 | $126,862 | Form 4 |
| Sep 1, 2026 | Phyllis GotlibPresident, International | Sold | 3,573 | $11.80 | $42,161 | Form 4 |
| Sep 1, 2026 | Paul Francis McNeiceChief Accounting Officer | Sold | 112 | $11.80 | $1,322 | Form 4 |
| Jul 1, 2026 | Dmitry ZamanskyChief Product & Tech. Officer | Sold | 8,460 | $9.33 | $78,932 | Form 4 |
| Jul 1, 2026 | Phyllis GotlibPresident, International | Sold | 6,677 | $9.33 | $62,296 | Form 4 |
| Jul 1, 2026 | Mark HirschhornChief Financial Officer | Sold | 4,299 | $9.33 | $40,110 | Form 4 |
| Jul 1, 2026 | Paul Francis McNeiceChief Accounting Officer | Sold | 653 | $9.33 | $6,092 | Form 4 |
| Jun 11, 2026 | Stephen J. SchlegelDirector | Sold plan | 9,750 | $8.76 | $85,410 | Form 4 |
| Jun 1, 2026 | Mark HirschhornChief Financial Officer | Sold | 10,761 | $9.74 | $104,812 | Form 4 |
| Jun 1, 2026 | Phyllis GotlibPresident, International | Sold | 3,573 | $9.74 | $34,801 | Form 4 |
| Jun 1, 2026 | Paul Francis McNeiceChief Accounting Officer | Sold | 112 | $9.74 | $1,091 | Form 4 |
| May 7, 2026 | Ido SchoenbergChairman, co-CEO, Director | Bought | 670 | $7.37 | $4,938 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −63.9% | −51.9% | −28.4% |
| Altman Z'' | −9.04 | −12.18 | −16.00 |
| Accruals ratio | −58.3% | −15.8% | −7.8% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put Amwell side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Amwell | FY25 | −2.0% | −42.2% | −26.5% | — | — | — | |
| Omada Health | FY25 | 53.2% | −4.6% | 6.5% | — | — | — | Compare |
| HealthStream | FY25 | 4.3% | 6.7% | 19.6% | — | — | — | Compare |
| Health Catalyst | FY25 | 1.5% | −51.7% | −0.1% | −38.6% | — | 4 | Compare |
| HeartFlow | FY25 | 39.9% | −36.4% | −33.5% | — | — | — | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 114 | 149 | 245 | 253 | 277 | 259 | 254 | 249 |
| Revenue growth | — | 30.6% | 64.8% | 3.1% | 9.7% | −6.5% | −1.8% | −2.0% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 36 | 54 | 84 | 107 | 138 | 106 | 86 | 73 |
| Operating income | −55 | −95 | −227 | −179 | −276 | −692 | −218 | −105 |
| Net income | −53 | −87 | −224 | −176 | −270 | −675 | −208 | −96 |
| Diluted EPS (US$) | −26.00 | −42.40 | −45.40 | −13.80 | −19.72 | −47.50 | −13.88 | −5.96 |
| Diluted shares (millions) | 2 | 2 | 5 | 13 | 14 | 14 | 15 | 16 |
| Cash flow | ||||||||
| Cash from operations | −74 | −82 | −112 | −142 | −192 | −148 | −127 | −66 |
| Capital expenditure | 2 | 1 | 3 | 1 | 0 | 0 | 0 | 0 |
| Free cash flow | −76 | −83 | −116 | −142 | −193 | −149 | −127 | −66 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 38 | 15 | 0 | 1 | 0 | 0 |
| Acquisitions | 64 | 46 | 0 | 156 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 12 | 118 | 44 | 68 | 72 | 48 | 22 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 48 | 178 | 1,042 | — | 538 | 372 | 228 | 182 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | — | 500 | 1,377 | 1,446 | 1,218 | 590 | 436 | 324 |
| Total liabilities | — | 125 | 130 | 185 | 134 | 110 | 120 | 76 |
| Shareholders' equity | −204 | −307 | 1,224 | 1,239 | 1,064 | 464 | 305 | 236 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | −48.4% | −63.6% | −92.7% | −70.9% | −99.5% | −267.2% | −85.5% | −42.2% |
| Net margin | −46.2% | −58.6% | −91.5% | −69.8% | −97.6% | −260.6% | −81.8% | −38.4% |
| Free cash flow margin | −66.6% | −55.9% | −47.2% | −56.2% | −69.5% | −57.3% | −50.1% | −26.5% |
| Rule of 40 (growth + FCF margin) | — | −25.3% | 17.6% | −53.1% | −59.8% | −63.9% | −51.9% | −28.4% |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | — | −49.0% | −14.3% | −23.5% | −88.4% | −54.1% | −35.4% |
| Return on assets | — | — | −23.9% | −12.5% | −20.3% | −74.7% | −40.6% | −25.2% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |